Zynerba Pharmaceuticals (NASDAQ:ZYNE) Given Daily Media Sentiment Score of 0.24


Where the relative strength index (RSI) is a technical momentum indicator that compares the magnitude of recent gains to recent losses in an attempt to determine excess buying & selling conditions of an asset, it is one of the most popular technical indicators, computed on the basis of the speed and direction of a stock's price movement. HC Wainwright's target price indicates a potential upside of 4.95% from the stock's current price.

A number of other brokerages have also weighed in on ZYNE. Zacks Investment Research cut Zynerba Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday, May 30th. Jefferies Group LLC reaffirmed a "buy" rating and issued a $32.00 price target on shares of Zynerba Pharmaceuticals in a report on Thursday, May 25th. The rating was initiated by Oppenheimer with "Outperform" on Tuesday, September 8.

Shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) plummets -54.18% in Monday's pre-session trade.

Among 18 analysts covering ElringKlinger (ETR:ZIL2), 5 have Buy rating, 6 Sell and 7 Hold. The company has market cap of $85.69 million. INFN's distance from 20 day simple moving average is -17.43% and distance from 50-Day simple moving average is -14.15%.

Zynerba Pharmaceuticals, Inc. (ZYNE) stock exposed a turn of -4.80% in most recent week and accomplished -12.08% performance over the last one month. However a year ago for the same quarter the company has reported $-0.67 EPS. On average, equities analysts predict that Zynerba Pharmaceuticals will post ($2.46) EPS for the current year.

TRADEMARK VIOLATION NOTICE: "Zynerba Pharmaceuticals, Inc". If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of US and global trademark & copyright law. The legal version of this report can be viewed at https://weekherald.com/2017/08/08/zynerba-pharmaceuticals-nasdaqzyne-getting-somewhat-negative-press-coverage-analysis-shows.html. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 25.85% with $10.57 Million sitting short, betting on future declines. The shares were acquired at an average price of $19.82 per share, with a total value of $103,064.00. The purchase was disclosed in a filing with the SEC, which is available through this link. Following the completion of the transaction, the chairman now owns 336,012 shares in the company, valued at $6,619,436.40.

The stock of Zynerba Pharmaceuticals Incorporated (NASDAQ:ZYNE) registered an increase of 0.02% in short interest.

Shares of Zynerba Pharmaceuticals (ZYNE) traded down 3.90% during trading on Tuesday, hitting $6.41.

The shares performance of ZYNE was -62.25% for the last one month and -52.70% in the previous week, whereas year to date performance was calculated -57.22%.

In other Zynerba Pharmaceuticals news, Chairman Armando Anido purchased 5,000 shares of the firm's stock in a transaction that occurred on Monday, May 15th. Sphera Funds Management LTD. bought a new stake in Zynerba Pharmaceuticals during the first quarter worth about $2,010,000. The firm's institutional ownership remained 95.90% while insider ownership included 2.30%.

Zynerba Pharmaceuticals, Inc. engages in the research and development of drugs.

ZYN002, a synthetic transdermal cannabidiol gel, failed to demonstrate a statistically significant reduction of focal seizures with either the high or low dose compared to placebo. Its clinical programs include synthetic cannabinoid therapeutics and patch and gel for transdermal delivery.